Zaid Tamimi1, Rola Al Habashneh2, Islam Hamad3, Mutasim Al-Ghazawi4, Ala' Abu Roqa'a5, Hamza Kharashgeh6. 1. Department Oral Surgery and Oral Medicine, Jordan University of Science and Technology, Irbid, Jordan. zztamimi@just.edu.jo. 2. Department Periodontology, Jordan University of Science and Technology, Irbid, Jordan. 3. Department of Pharmacy, American University of Madaba, Amman, Jordan. 4. Department of Biopharmaceutics and Clinical Pharmacy, The University of Jordan, Amman, Jordan. 5. The First for Research and Development LLC, Amman, Jordan. 6. Department Oral Surgery and Oral Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Abstract
BACKGROUND:Serratiopeptidase has been clinically used in controlling surgical and non-surgical inflammatory conditions. This study was conducted to assess the therapeutic effect of Serratiopeptidase in patients undergoing surgical removal of impacted mandibular third molar. METHODS: This randomized clinical trial investigated the efficacy of Serratiopeptidase and Paracetamol after surgical removal of impacted third molar for 5 days (n = 67) as compared with an equivalent dose of placebo and Paracetamol (n = 66). Outcome measures were reported pain, trismus and swelling using Laskin method. All outcome measures were recorded on days 0, 1, 2, 4, and 5 post-surgeries. RESULTS: In this clinical trail 133 patients (mean age 23 years, 54% female) completed the study. Baseline characteristics were comparable across treatment groups. Serratiopeptidase significantly improved trismus compared with control on the 4th day (27.30 ± 7.3 mm and 32.06 ± 7.7 mm, respectively (P < 0.001) Swelling markedly improved, The distance from the lower edge of the earlobe to the midpoint of the symphysis for cases vs control were 111.49 ± 8.1 mm and 115.39 ± 9.9 mm, respectively (P < 0.001). Reported pain, showed no statistical significance difference. CONCLUSION:Serratiopeptidase resulted in better inflammation improvement than placebo over 5 days. Further studies are warranted to assess longer-term and clinical outcomes, as well as safety. CLINICAL RELEVANCE: Serratiopeptidase administered postoperatively helps in improving trismus and swelling after removal of impacted lower third molars. Trial registration The study was registered in ClinicalTrial.gov under the number NCT02493179. Registered 1st of June 2015, https://clinicaltrials.gov/ct2/results?cond=serratiopeptidase .
RCT Entities:
BACKGROUND: Serratiopeptidase has been clinically used in controlling surgical and non-surgical inflammatory conditions. This study was conducted to assess the therapeutic effect of Serratiopeptidase in patients undergoing surgical removal of impacted mandibular third molar. METHODS: This randomized clinical trial investigated the efficacy of Serratiopeptidase and Paracetamol after surgical removal of impacted third molar for 5 days (n = 67) as compared with an equivalent dose of placebo and Paracetamol (n = 66). Outcome measures were reported pain, trismus and swelling using Laskin method. All outcome measures were recorded on days 0, 1, 2, 4, and 5 post-surgeries. RESULTS: In this clinical trail 133 patients (mean age 23 years, 54% female) completed the study. Baseline characteristics were comparable across treatment groups. Serratiopeptidase significantly improved trismus compared with control on the 4th day (27.30 ± 7.3 mm and 32.06 ± 7.7 mm, respectively (P < 0.001) Swelling markedly improved, The distance from the lower edge of the earlobe to the midpoint of the symphysis for cases vs control were 111.49 ± 8.1 mm and 115.39 ± 9.9 mm, respectively (P < 0.001). Reported pain, showed no statistical significance difference. CONCLUSION: Serratiopeptidase resulted in better inflammation improvement than placebo over 5 days. Further studies are warranted to assess longer-term and clinical outcomes, as well as safety. CLINICAL RELEVANCE: Serratiopeptidase administered postoperatively helps in improving trismus and swelling after removal of impacted lower third molars. Trial registration The study was registered in ClinicalTrial.gov under the number NCT02493179. Registered 1st of June 2015, https://clinicaltrials.gov/ct2/results?cond=serratiopeptidase .
Authors: A Mazzone; M Catalani; M Costanzo; A Drusian; A Mandoli; S Russo; E Guarini; G Vesperini Journal: J Int Med Res Date: 1990 Sep-Oct Impact factor: 1.671
Authors: L Aznar-Arasa; K Harutunian; R Figueiredo; E Valmaseda-Castellón; C Gay-Escoda Journal: Int J Oral Maxillofac Surg Date: 2012-04-20 Impact factor: 2.789
Authors: Mouneshkumar Chappi D; Kandagal V Suresh; Manisha R Patil; Rajendra Desai; David P Tauro; Shiva Bharani K N S; Mushtaq I Parkar; Harsha V Babaji Journal: J Clin Exp Dent Date: 2015-04-01